Good play on a speculative migraine pain management device.
Around 600 M shares outstanding with low float and virtually no debt.
A small investment in
ADHC could yield exponential returns in a few short years.
Market cap could exceed to over $1B+ with successful FDA and clinical studies then successful marketplace execution.
Over $1 PPS is not unreasonable with this massive pain management market.
Good luck to longs.
Around 600 M shares outstanding with low float and virtually no debt.
A small investment in
ADHC could yield exponential returns in a few short years. Market cap could exceed to over $1B+ with successful FDA and clinical studies then successful marketplace execution.
Over $1 PPS is not unreasonable with this massive pain management market.
Good luck to longs.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。